The past, present and future of renin-angiotensin aldosterone system inhibition

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 1677-1687

  Mentz, Robert J ^a   Bakris, George L ^b   Waeber, Bernard ^c   McMurray, John J V ^d   Gheorghiade, Mihai ^e   Ruilope, Luis M ^f   Maggioni, Aldo P ^g   Swedberg, Karl ^h   Piña, Ileana L ⁱ   Fiuzat, Mona ^a   O'Connor, Christopher M ^a   Zannad, Faiez ^j   Pitt, Bertram ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g ANMCO RESEARCH CENTER   (Italy)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j Centre d'Investigations Cliniques   (France)

^k UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

more..

Author keywords

Clinical trials; Heart failure; Hypertension; Myocardial infarction; Renin angiotensin aldosterone system

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZILSARTAN; AZILSARTAN MEDOXOMIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; IRBESARTAN; LCI 699; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; OLMESARTAN; OMAPATRILAT; PATIROMER; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MASTALGIA; MAXIMUM TOLERATED DOSE; MENSTRUATION DISORDER; MICROALBUMINURIA; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC HEART FAILURE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; HEART FAILURE; HYPERTENSION; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84883263452     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.007     Document Type: Review

References (129)

1. C.M. Ferrario, and W.B. Strawn Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease Am J Cardiol 98 2006 121 128
2. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Eng J Med 316 1987 1429 1435
3. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Eng J Med 341 1999 709 717
4. A.H. Gradman Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention Am Heart J 157 2009 S1 S6
5. M.M. Givertz Manipulation of the renin-angiotensin system Circulation 104 2001 E14 E18
6. G.H. Gibbons, and V.J. Dzau The emerging concept of vascular remodeling N Eng J Med 330 1994 1431 1438
7. V.J. Dzau Tissue renin-angiotensin system in myocardial hypertrophy and failure Arch Intern Med 153 1993 937 942
8. C. Zitnay, and H.M. Siragy Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis Miner Electrolyte Metab 24 1998 362 370
9. J.A. Leopold Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling Circulation 124 2011 e466 e468
10. M.R. Weir, and V.J. Dzau The renin-angiotensin-aldosterone system: a specific target for hypertension management Am J Hypertens 12 1999 205S 213S
11. M.R. Hayden, and J.R. Sowers Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome J Am Soc Hypertens 2 2008 239 266
12. Y. Takeda Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist Hypertension Research: Official Journal of the Japanese Society of Hypertension 27 2004 781 789
13. N.J. Brown Eplerenone: cardiovascular protection Circulation 107 2003 2512 2518
14. T. Konoshita Do genetic variants of the renin-angiotensin system predict blood pressure response to renin-angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the renin-angiotensin system Curr Hypertens Rep 13 2011 356 361
15. S.K. Patel, B. Wai, and M. Ord Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes Am J Hypertens 25 2012 216 222
16. N.J. Brown, and D.E. Vaughan Angiotensin-converting enzyme inhibitors Circulation 97 1998 1411 1420
17. M. Burnier, and H.R. Brunner Angiotensin II receptor antagonists Lancet 355 2000 637 645
18. Z.H. Israili Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 14 Suppl. 1 2000 S73 S86
19. M.A. Munger Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions P T 36 2011 22 40
20. M. de Gasparo, U. Joss, and H.P. Ramjoue Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro J Pharmacol Exp Ther 240 1987 650 656
21. A.H. Gradman, and R. Kad Renin inhibition in hypertension J Am Coll Cardiol 51 2008 519 528
22. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators N Eng J Med 325 1991 293 302
23. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450 1456
24. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
25. C.B. Granger, J.J. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
26. M.A. Konstam, J.D. Neaton, and K. Dickstein Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial Lancet 374 2009 1840 1848
27. B. Pitt, P.A. Poole-Wilson, and R. Segal Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II Lancet 355 2000 1582 1587
28. S. Yusuf, M.A. Pfeffer, and K. Swedberg Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
29. B.M. Massie, P.E. Carson, and J.J. McMurray Irbesartan in patients with heart failure and preserved ejection fraction N Eng J Med 359 2008 2456 2467
30. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Eng J Med 345 2001 1667 1675
31. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
32. A.D. Struthers Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure J Card Fail 2 1996 47 54
33. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
34. A.S. Desai, E.F. Lewis, and R. Li Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2011 966 972 [e10]
35. S.A. Hunt, W.T. Abraham, and M.H. Chin 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 e391 e479
36. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J Fail 14 2012 803 869
37. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr., and T.E. Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Eng J Med 327 1992 669 677
38. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
39. L. Kober, C. Torp-Pedersen, and J.E. Carlsen A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N Eng J Med 333 1995 1670 1676
40. M.A. Pfeffer, J.J. McMurray, and E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Eng J Med 349 2003 1893 1906
41. K. Dickstein, and J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760
42. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction Lancet 343 1994 1115 1122
43. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction Lancet 345 1995 669 685
44. E. Ambrosioni, C. Borghi, and B. Magnani The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators N Eng J Med 332 1995 80 85
45. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Eng J Med 348 2003 1309 1321
46. F. Beygui, E. Vicaut, and P. Ecollan Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial Am Heart J 160 2010 642 648
47. E.M. Antman, M. Hand, and P.W. Armstrong 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 2008 210 247
48. R.S. Wright, J.L. Anderson, and C.D. Adams 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 e215 e367
49. F. Van de Werf, J. Bax, and A. Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
50. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
51. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
52. S. Julius, S.E. Kjeldsen, and M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
53. L.M. Wing, C.M. Reid, and P. Ryan A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Eng J Med 348 2003 583 592
54. H. Lithell, L. Hansson, and I. Skoog The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
55. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
56. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
57. T. Krause, K. Lovibond, M. Caulfield, T. McCormack, and B. Williams Management of hypertension: summary of NICE guidance BMJ 343 2011 d4891
58. E. Braunwald, M.J. Domanski, and S.E. Fowler Angiotensin-converting- enzyme inhibition in stable coronary artery disease N Eng J Med 351 2004 2058 2068
59. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Eng J Med 342 2000 145 153
60. K.M. Fox Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
61. S. Yusuf, K. Teo, and C. Anderson Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
62. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Eng J Med 345 2001 861 869
63. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Eng J Med 345 2001 851 860
64. R.O. Estacio, B.W. Jeffers, W.R. Hiatt, S.L. Biggerstaff, N. Gifford, and R.W. Schrier The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Eng J Med 338 1998 645 652
65. P. Tatti, M. Pahor, and R.P. Byington Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 597 603
66. M. Pahor, B.M. Psaty, M.H. Alderman, W.B. Applegate, J.D. Williamson, and C.D. Furberg Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Diabetes Care 23 2000 888 892
67. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ 317 1998 713 720
68. H. Haller, S. Ito, and J.L. Izzo Jr. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Eng J Med 364 2011 907 917
69. L.F. Fried, W. Duckworth, and J.H. Zhang Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) Clin J Am Soc Nephrol 4 2009 361 368
70. R.S. Vasan, J.C. Evans, and M.G. Larson Serum aldosterone and the incidence of hypertension in nonhypertensive persons N Eng J Med 351 2004 33 41
71. N. Chapman, J. Dobson, and S. Wilson Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 2007 839 845
72. F. de Souza, E. Muxfeldt, R. Fiszman, and G. Salles Efficacy of spironolactone therapy in patients with true resistant hypertension Hypertension 55 2010 147 152
73. J. Vaclavik, R. Sedlak, and M. Plachy Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial Hypertension 57 2011 1069 1075
74. J.W. Funder, R.M. Carey, and C. Fardella Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline J Clin Endocrinol Metab 93 2008 3266 3281
75. B. Pitt, N. Reichek, and R. Willenbrock Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study Circulation 108 2003 1831 1838
76. J.M. Flack, S. Oparil, and J.H. Pratt Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients J Am Coll Cardiol 41 2003 1148 1155
77. J.P. Bertocchio, D.G. Warnock, and F. Jaisser Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease Kidney Int 79 2011 1051 1060
78. N.K. Hollenberg Aldosterone in the development and progression of renal injury Kidney Int 66 2004 1 9
79. M. Epstein, G.H. Williams, and M. Weinberger Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 2006 940 951
80. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, and G.F. Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease Cochrane Database Syst Rev 3 2009 1 39
81. A.J. Viera Resistant hypertension J Am Board Fam Med 25 2012 487 495
82. M.J. Brown, G.T. McInnes, C.C. Papst, J. Zhang, and T.M. MacDonald Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial Lancet 377 2011 312 320
83. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, and N.K. Hollenberg Aliskiren combined with losartan in type 2 diabetes and nephropathy N Eng J Med 358 2008 2433 2446
84. S.D. Solomon, E. Appelbaum, and W.J. Manning Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation 119 2009 530 537
85. H.H. Parving, B.M. Brenner, and J.J. McMurray Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant 24 2009 1663 1671
86. European Medicines Agency European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines [Accessed online at] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ public-health-alerts/2012/02/human-pha-detail-000055.jsp&mid= WC0b01ac058001d126# February 16 2012 [March 3, 2012]
87. J.B. Kostis, M. Packer, H.R. Black, R. Schmieder, D. Henry, and E. Levy Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 2004 103 111
88. FDA US Food and Drug Administration Aliskiren-containing medications: drug safety comunication - new warning and contraindication. April 20, 2012 http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm301120.htm 2012
89. O.D. Pedersen, H. Bagger, L. Kober, and C. Torp-Pedersen Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
90. E. Vermes, J.C. Tardif, and M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2003 2926 2931
91. A.G. Zaman, M.T. Kearney, C. Schecter, S.G. Worthley, and J. Nolan Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation Am Heart J 147 2004 823 827
92. A.H. Madrid, M.G. Bueno, and J.M. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 2002 331 336
93. J.S. Healey, A. Baranchuk, and E. Crystal Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis J Am Coll Cardiol 45 2005 1832 1839
94. M.P. Schneider, T.A. Hua, M. Bohm, K. Wachtell, S.E. Kjeldsen, and R.E. Schmieder Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis J Am Coll Cardiol 55 2010 2299 2307
95. H. Nakashima, K. Kumagai, H. Urata, N. Gondo, M. Ideishi, and K. Arakawa Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation Circulation 101 2000 2612 2617
96. M. Disertori, R. Latini, and S. Barlera Valsartan for prevention of recurrent atrial fibrillation N Eng J Med 360 2009 1606 1617
97. S. Yusuf, J.S. Healey, and J. Pogue Irbesartan in patients with atrial fibrillation N Eng J Med 364 2011 928 938
98. K. Swedberg, F. Zannad, and J.J. McMurray Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study J Am Coll Cardiol 59 2012 1598 1603
99. M. Disertori, S. Barlera, L. Staszewsky, R. Latini, S. Quintarelli, and M.G. Franzosi Systematic review and meta-analysis: renin-Angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: An unfulfilled hope. Cardiovasc Drugs Ther 26 2012 47 54
100. A. Ducharme, and E.L. Schiffrin Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation Can J Cardiol 26 Suppl. E 2010 21E 23E
101. I. Savelieva, N. Kakouros, A. Kourliouros, and A.J. Camm Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention Europace 13 2011 610 625
102. A.G. Chiu, E.J. Krowiak, and Z.E. Deeb Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology Laryngoscope 111 2001 1729 1731
103. C.J. Beavers, S.P. Dunn, and T.E. Macaulay The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema Ann Pharmacother 45 2011 520 524
104. N. Khosla, R. Kalaitzidis, and G.L. Bakris Predictors of hyperkalemia risk following hypertension control with aldosterone blockade Am J Nephrol 30 2009 418 424
105. B. Pitt, S.D. Anker, D.A. Bushinsky, D.W. Kitzman, F. Zannad, and I.Z. Huang Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial Eur Heart J 32 2011 820 828
106. R.S. Stafford, and D.C. Radley The underutilization of cardiac medications of proven benefit, 1990 to 2002 J Am Coll Cardiol 41 2003 56 61
107. M. Packer, P.A. Poole-Wilson, and P.W. Armstrong Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation 100 1999 2312 2318
108. S. Yusuf, K.K. Teo, and J. Pogue Telmisartan, ramipril, or both in patients at high risk for vascular events N Eng J Med 358 2008 1547 1559
109. J.J. McMurray, B. Pitt, and R. Latini Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 2008 17 24
110. M. Gheorghiade, M. Albaghdadi, and F. Zannad Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) Eur J Heart Fail 13 2011 100 106
111. H. Krum, B. Massie, and W.T. Abraham Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study Eur J Heart Fail 13 2011 107 114
112. J.J. McMurray, W.T. Abraham, K. Dickstein, L. Kober, B.M. Massie, and H. Krum Aliskiren, ALTITUDE, and the implications for ATMOSPHERE Eur J Heart Fail 14 2012 341 343
113. S.D. Solomon, S.H. Shin, and A. Shah Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction Eur Heart J 32 2011 1227 1234
114. S. Lam Azilsartan: a newly approved angiotensin II receptor blocker Cardiol Rev 19 2011 300 304
115. W.B. White, M.A. Weber, and D. Sica Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension Hypertension 57 2011 413 420
116. D. Sica, W.B. White, and M.A. Weber Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring J Clin Hypertens (Greenwich) 13 2011 467 472
117. G.L. Bakris, D. Sica, and M. Weber The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure J Clin Hypertens (Greenwich) 13 2011 81 88
118. J.W. Funder Aldosterone and mineralocorticoid receptors in the cardiovascular system Prog Cardiovasc Dis 52 2010 393 400
119. S. Takai, D. Jin, M. Muramatsu, K. Kirimura, H. Sakonjo, and M. Miyazaki Eplerenone inhibits atherosclerosis in nonhuman primates Hypertension 46 2005 1135 1139
120. L. Amar, M. Azizi, J. Menard, S. Peyrard, C. Watson, and P.F. Plouin Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism Hypertension 56 2010 831 838
121. D.A. Calhoun, W.B. White, and H. Krum Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial Circulation 124 2011 1945 1955
122. M. Packer, R.M. Califf, and M.A. Konstam Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
123. L.M. Ruilope, A. Dukat, M. Bohm, Y. Lacourciere, J. Gong, and M.P. Lefkowitz Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 2010 1255 1266
124. T. Unger, L. Paulis, and D.A. Sica Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches Eur Heart J 32 2011 2739 2747
125. S.D. Solomon, M. Zile, and B. Pieske The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
126. S. Der Sarkissian, M.J. Huentelman, J. Stewart, M.J. Katovich, and M.K. Raizada ACE2: a novel therapeutic target for cardiovascular diseases Prog Biophys Mol Biol 91 2006 163 198
127. S. Epelman, W.H. Tang, S.Y. Chen, F. Van Lente, G.S. Francis, and S. Sen Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin- aldosterone system J Am Coll Cardiol 52 2008 750 754
128. S. Epelman, K. Shrestha, and R.W. Troughton Soluble angiotensin- converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes J Card Fail 15 2009 565 571
129. L. Paulis, and T. Unger Novel therapeutic targets for hypertension Nat Rev Cardiol 7 2010 431 441